Sindhura Saini
Psychiatry · Saint Louis, MONPI 1598062267
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,087 and has fallen 67.5% since, to $354 in 2023.
Across 156 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$517
- Neuronetics, Inc.$354
- AbbVie$350
- Takeda Pharmaceuticals U.S.A., Inc.$338
- Otsuka America Pharmaceutical, Inc.$152
- Vanda Pharmaceuticals Inc.$151
- plus $691 from 12 others
What the payments were for
- Food & beverage$2,52299%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 35 | $517 |
| Neuronetics, Inc. | 1 | $354 |
| AbbVie(2 entities) | 22 | $350 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $338 |
| Otsuka America Pharmaceutical, Inc. | 12 | $152 |
| Vanda Pharmaceuticals Inc. | 9 | $151 |
| Supernus Pharmaceuticals, Inc. | 12 | $128 |
| Johnson & Johnson | 6 | $111 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $91 |
| Lundbeck LLC | 5 | $86 |
| Shire North American Group Inc | 5 | $68 |
| Corium, LLC | 4 | $61 |
| Neos Therapeutics, LP | 4 | $61 |
| Ironshore Pharmaceuticals Inc. | 2 | $27 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Merck | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,552 in reported general payments places this provider in the 80th percentile of 680 psychiatry providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 40 | $744 |
| Quetiapine Fumarate | 18 | $548 |
| Escitalopram Oxalate | 21 | $367 |
| Clonazepam | 25 | $140 |
| Fluoxetine Hcl | 12 | $83 |
| Propranolol Hcl | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Saint Louis
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- George GrossbergSaint Louis$501K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.